Replies to post #214782 on Biotech Values

[DewDiligence]

(RVNC)—Allergan's loyalty program is no big deal. It offers a point system with minuscule cash rebates for repeat users.

[DewDiligence]

No mention of IP protection or lawsuits against Revance.

It would be counter-productive for AGN to comment on potential litigation at this stage.

[kris_kade]

The fact AGN is saying ‘it will have its place” for RT002, their comment implies they acknowledge tacitly RT002 is a differentiator.

They clearly getting prepared for meaningful competition (Revance) for the first time.